Cancer Biopsy Market Size, Share & Trends Report

Cancer Biopsy Market Size, Share & Trends Analysis Report By Product (Instruments, Kits & Consumables, Services), By Type (Tissue Biopsies, Liquid Biopsies), By Application, By Region, And Segment Forecasts, 2020 - 2027

  • Published Date: Dec, 2020
  • Base Year for Estimate: 2019
  • Report ID: GVR-4-68039-254-2
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2018
  • Number of Pages: 140

Report Overview

The global cancer biopsy market size was valued at USD 19.97 billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of 6.33% from 2020 to 2027. The emerging significance of cancer biopsies and tissue sectioning in providing important information with respect to oncological molecular profiling, coupled with the advent of non-invasive liquid biopsies, has propelled the market growth. Several techniques including bone marrow, endoscopic, needle, skin, and surgical biopsies are incorporated in the oncology diagnostics field. Of these techniques, needle biopsies are the most performed technique aimed at the early detection of patients. Whereas benefits offered by fine needle aspiration (FNA) type needle biopsies include shorter wait time for the results, along with minimal incision on the skin, which has contributed to the overall demand for biopsy-based diagnosis of patients.

Japan cancer biopsy market size, by application, 2016 - 2027 (USD Billion)

Some of these techniques demand surgical incisions including staging splenectomy for patients suffering from Hodgkin’s lymphoma; while other patients undergo minimal incision or none at all such as fine needle aspiration biopsies of patients suffering from liver, breast, lung, and thyroid cancers. Successful implementation of these techniques demands using the right biopsy type for the right patients, appropriate sample processing, and accurate pathological examination.

Additionally, a series of advancements in image-guided biopsies and expanding applications of the same has been marked as a key trend in recent years. For instance, in 2017, magnetic resonance imaging targeted biopsies were evaluated for their potential in prostate tumor detection.

The study concluded that multiparametric magnetic resonance (MR) imaging-based biopsies helped in minimizing false negative results further enhancing risk assessment. Moreover, various companies operating in data analysis and diagnostics are entering this market.

This test confirms tumor presence via the identification of genetic markers in the blood. This technique is gaining immense popularity since its inception owing to the benefits associated with it such as cost effectiveness, lesser complexity and time consumption, and minimal pain during the biopsy.

Product Insights

Kits and consumables led the market and accounted for over 60.0% share in 2019 as these are integral across various stages of biopsies and robust investments by key players operating in this industry have made significant contributions. This is also supplemented by a considerable increase in the number of patients across the globe that demand instruments and kits to be efficient, accurate, and rapid.

Cancer biopsy has witnessed several developments in terms of instruments, kits, and consumables. With liquid biopsy emerging as a multimodal tool of diagnosis in the field of clinical oncology, the development of efficient products associated with biopsies is pivotal. Though the existing instruments are used predominantly, they are accompanied by various shortcomings. However, the advent of novel technologies is expected to significantly increase the demand for instruments in the coming years.

Several emerging manufacturers are focusing on launching instruments that are able to enhance endoscopy-based biopsies. For instance, BiBBInstruments AB, a Swedish company, has established a strong presence in the instruments market space under the brand - EndoDrill.

Type Insights

The tissue biopsies segment dominated the market and accounted for 86.03% share of the total revenue in 2019. These are still considered to be a mainstay of biopsies and are largely adopted across various cancer diagnosis applications. This is attributed to robust research activities evaluating their safety and efficacy, which has contributed to the segment growth in the global market.

Advancements targeted towards enhancing tissue biopsy procedures are expected to maintain the segment’s lead in the global market for the next few years. For instance, Cernostics is developing an assay suitable for diagnosing cancer patients suffering from Barrett's Esophagus. This one-of-a-kind diagnostic test makes use of biopsy images that are digitally scanned, which aids in the analysis and quantification of alterations occurring at the cellular or molecular levels within a tissue.

Technological developments pertaining to circulating biomarkers detection in blood samples derived from patients allow non-hematologic cancer diagnosis through non-invasive techniques. Liquid biopsy is considered to be a more practical approach to real-time patient monitoring as compared to conventional tumor biopsies.

Liquid biopsy tests are inclusive of markers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs). Exosomes are known to have the ability to alter treatment and manage the dynamics related to disease progression.

The rising preference for liquid biopsy among physicians has been observed in recent years, which is supplemented by its ability to offer disease snapshots from the primary and distant tumor sites. This approach is put to use in personalized medicine treatment, wherein tumor markers are sampled repeatedly to alter the therapy based on the patient’s response to the treatment.

Application Insights

Breast cancer emerged as the dominant segment and accounted for over 14.0% share of the total revenue in 2019. Breast cancer has the largest prevalence rate. Around 1 in 8 U.S. women develop invasive breast cancer as per the U.S. breast cancer statistics. An estimated 276,480 new cases of invasive breast cancer are expected to be diagnosed in women in 2020 in the U.S., along with more than 40,000 new non-invasive breast cancer cases.

Patients suspected of the onset of breast cancer are subjected to microscopic analysis of breast tissue, which is mandatory to obtain a definitive diagnosis along with detecting the stage and characterization of type. This has propelled the demand for a needle biopsy or surgical biopsy to obtain tissue for microscopic analysis, in turn, contributing to the segment growth.

Global cancer biopsy market share, by application, 2019 (%)

A significant increase in the number of patients across the globe, especially in the case of lung, breast, and colorectal cancers, has propelled the adoption of various biopsy techniques, including fine needle aspiration as well as core needle technique, especially for breast biopsies.

Circulating tumor cells (CTC)-based liquid biopsies have the ability to track the minimal residual disease (MRD) in non-metastatic prostate cancer patients, along with the follow-up evaluations performed to offer independent prognostic insights. A novel European project named Transcan—PROLIPSY is designed to assess the potential of combined use of CTCs, exosomes, and ctDNA as a non-invasive liquid biopsy modality to diagnose prostate cancer, followed by its routine evaluation.

Regional Insights

North America held the largest revenue share of over 37.0% in 2019. North America is anticipated to maintain its lead throughout the forecast, with the U.S. making significant contributions to the regional revenue. In addition, distributors and manufacturers operating in this region aim to distribute as well as develop novel kits that are well-suited for rapid diagnostic applications.

Moreover, the increasing adoption of liquid biopsies across the U.S. is largely favored by the profitable strategies laid out by the respective government authorities. Regulatory strategies for liquid biopsy-based oncology diagnostics rely on the framework, which has been developed in recent years by the U.S. Food and Drug Administration (FDA).

This framework is comprised of the guidelines associated with enrichment biomarkers as well as companion diagnostics, and approval precedents. The ultimate success of liquid biopsy regulatory pathways has been supplemented by the increased value for the Clinical Laboratory Improvement Amendment (CLIA)‐developed tests, which have been approved by the FDA.

Key Companies & Market Share Insights

Key players in the market are contributing to market growth by expanding their diagnostics portfolio, further enhancing the uptake of their proprietary biopsy products. For instance, in February 2020, Qiagen received CE Mark for its mutation assay namely, Therascreen PIK3CA RGQ PCR kit, which is developed to detect breast cancer patients with PIK3CA mutation.

Liquid biopsy samples (blood specimens) have to be used with this kit to quantify certain mutations associated with circulating tumor DNA (ctDNA). This product was co-developed by Qiagen and Novartis in the U.S. and with this CE approval, the product is expected to capture the European market. Some prominent companies in the global cancer biopsy market include:

  • Qiagen N.V.

  • Illumina, Inc.

  • ANGLE Plc

  • BD (Becton, Dickinson And Company)

  • Myriad Genetics

  • Hologic, Inc.

  • Biocept, Inc.

  • Thermo Fisher Scientific, Inc.

  • Danaher

  • F. Hoffmann-La Roche Ltd.

  • Lucence Diagnostics Pte. Ltd.

  • GRAIL, Inc.

  • Guardant Health

  • Exact Sciences Corporation

  • Freenome Holdings, Inc.

  • Biodesix (Integrated Diagnostics)

  • Oncimmune

  • Epigenomics AG

  • HelioHealth (Laboratory for Advanced Medicine)

  • Genesystems, Inc. (Genesys Biolabs)

  • Chronix Biomedical, Inc.

  • Personal Genome Diagnostics Inc.

  • Natera, Inc.

  • Personalis Inc.

Cancer Biopsy Market Report Scope 

Report Attribute


Market size value in 2020

USD 21.55 billion

Revenue forecast in 2027

USD 32.63 billion

Growth Rate

CAGR of 6.33% from 2020 to 2027

Base year for estimation


Historical data

2016 - 2018

Forecast period

2020 - 2027

Quantitative units

Revenue in USD billion and CAGR from 2020 to 2027

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, type, application, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; Italy; Spain; France; China; Japan; India; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia

Key companies profiled

Qiagen N.V.; Illumina, Inc.; ANGLE Plc; BD (Becton, Dickinson And Company); Myriad Genetics; Hologic, Inc.; Biocept, Inc.; Thermo Fisher Scientific, Inc.; Danaher; F. Hoffmann-La Roche Ltd.; Lucence Diagnostics Pte. Ltd.; GRAIL, Inc.; Guardant Health; Exact Sciences Corporation; Freenome Holdings, Inc.; Biodesix (Integrated Diagnostics); Oncimmune; Epigenomics AG; HelioHealth (Laboratory for Advanced Medicine); Genesystems, Inc. (Genesys Biolabs); Chronix Biomedical, Inc.; Personal Genome Diagnostics Inc.; Natera, Inc.; Personalis Inc.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global cancer biopsy market report on the basis of product, type, application, and region:

  • Product Outlook (Revenue, USD Billion, 2016 - 2027)

    • Instruments

    • Kits and Consumables

    • Services

  • Type Outlook (Revenue, USD Billion, 2016 - 2027)

    • Tissue Biopsies

      • Needle Biopsies

        • Fine Needle Aspiration (FNA)

        • Core Needle Biopsy (CNB)

      • Surgical Biopsies

    • Liquid Biopsies

    • Others

  • Application Outlook (Revenue, USD Billion, 2016 - 2027)

    • Breast Cancer

    • Colorectal Cancer

    • Cervical Cancers

    • Lung Cancers

    • Prostate Cancers

    • Skin Cancers

    • Blood Cancers

    • Kidney Cancers

    • Liver Cancers

    • Pancreatic Cancers

    • Ovarian Cancers

    • Others

  • Regional Outlook (Revenue, USD Billion, 2016 - 2027)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Spain

      • Italy

    • Asia Pacific

      • Japan

      • China

      • India

      • Thailand

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

Pricing & Purchase Options

Service Guarantee

  • Insured Buying

    This report has a service guarantee. We stand by our report quality.

  • Confidentiality

    We are in compliance with GDPR & CCPR norms. All interactions are confidential.

  • Custom research service

    Design an exclusive study to serve your research needs.

  • 24/5 Research support

    Get your queries resolved from an industry expert.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities